Search

Your search keyword '"Garcia-Ropero A"' showing total 2 results
Start Over Author "Garcia-Ropero A" Journal cardiovascular drugs and therapy
2 results on '"Garcia-Ropero A"'

2. Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the 'Cardiac Benefits' of Empagliflozin Independent of its Hypoglycemic Activity?

Author

Anu Lala, Johanna Contreras, Vivian M. Abascal, Donna M. Mancini, Farah Atallah-Lajam, Ronald Tamler, Carlos G. Santos-Gallego, Icilma V. Fergus, Alvaro Garcia-Ropero, Sean Pinney, Javier Sanz, Juan J. Badimon, Valentin Fuster, and Pedro R. Moreno

Subjects
0301 basic medicine, Cardiac function curve, medicine.medical_specialty, Time Factors, Cardiomyopathy, Walk Test, 030204 cardiovascular system & hematology, Hypoglycemia, Ventricular Function, Left, 03 medical and health sciences, 0302 clinical medicine, Double-Blind Method, Glucosides, Internal medicine, Diabetes mellitus, Surveys and Questionnaires, medicine, Empagliflozin, Humans, Pharmacology (medical), Prospective Studies, Benzhydryl Compounds, Sodium-Glucose Transporter 2 Inhibitors, Randomized Controlled Trials as Topic, Pharmacology, Heart Failure, Ejection fraction, Exercise Tolerance, business.industry, Cardiovascular Agents, General Medicine, Recovery of Function, medicine.disease, Magnetic Resonance Imaging, Clinical trial, 030104 developmental biology, Treatment Outcome, Heart failure, cardiovascular system, Cardiology, Quality of Life, Ventricular Function, Right, New York City, Cardiology and Cardiovascular Medicine, business
Abstract

The SGLT2 inhibitor empagliflozin reduced cardiovascular mortality by 38% and heart failure (HF) hospitalizations by 35% in diabetic patients. We have recently demonstrated the efficacy of empagliflozin in ameliorating HF and improving cardiac function in a non-diabetic porcine model of HF mediated via a switch in myocardial metabolism that enhances cardiac energetics. Therefore, we hypothesized that the cardiac benefits of empagliflozin can also be extended to non-diabetic HF patients. The EMPA-TROPISM clinical trial is a randomized, double-blind, parallel group, placebo-controlled, trial comparing the efficacy of and safety of empagliflozin in non-diabetic HF patients. Eighty patients with stable HF for over 3 months, LVEF

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results